News Headlines
-
ExcellGene SA And Cytovance Biologics Join Forces To Transform Large Molecule Biologics Development And Manufacture
5/8/2024
ExcellGene SA, a leading Swiss biotech service provider specializing in mammalian cell line development for more than two decades, proudly announces its strategic collaboration with Cytovance Biologics, a renowned Contract Development and Manufacturing Organization (CDMO) based in the USA.
-
Siren Biotechnology And Catalent Enter Partnership For Manufacturing Of AAV Gene Therapies For Cancer
5/8/2024
Siren Biotechnology, pioneers of Universal AAV Immuno-Gene Therapy for Cancer, and Catalent Inc., the leader in enabling the development and supply of better treatments for patients worldwide, entered a strategic partnership to support the development and manufacturing of Siren Biotechnology’s AAV immuno-gene therapies.
-
MilliporeSigma Expands Its Optimized VirusExpress® Platform For Lentiviral Vectors, Further Enhancing Quality And De-Risking Cell And Gene Therapy Manufacturing
5/8/2024
MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, is pleased to announce the expansion of its VirusExpress® platform used in the development and manufacturing of lentiviral vectors.
-
ARTBIO And Nucleus RadioPharma Announce Collaboration To Manufacture GMP-Grade Therapeutic Products Containing Radioisotope Pb-212 To Support Emerging Clinical Trials
5/7/2024
ARTBIO, Inc. (ARTBIO), a clinical-stage radiopharmaceutical company developing a new class of targeted alpha radioligand therapies (ARTs), and Nucleus RadioPharma Inc. (Nucleus), the world’s first fully integrated development, manufacturing, and supply chain organization for radiopharmaceuticals, today announced a strategic manufacturing and supply agreement to support ARTBIO’s therapeutic product manufacturing.
-
Caring Cross And ImmunoAdoptive Cell Therapy (ImmunoACT) Announce Agreement To Commercialize TriCAR-T Cell Immunotherapy For Leukemia And Lymphoma
5/7/2024
Caring Cross, a 501(c)(3) non-profit dedicated to accelerating the development of advanced medicines and enabling access to cures for all patients, everywhere, and ImmunoAdoptive Cell Therapy (ImmunoACT), a Mumbai, India-based pioneering research and cell and gene therapy development company, announced an agreement to develop and commercialize a multi-targeted chimeric antigen receptor T-cell immunotherapy for leukemia and lymphoma.
-
Cellipont Bioservices And Adva Biotechnology Collaborate To Optimize Cell Therapy Manufacturing With The ADVA X3® Platform
5/7/2024
Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), and Adva Biotechnology, an Israel-based private biotechnology company providing a decentralized, automated, and efficient manufacturing platform for advanced cell therapies, today announce its partnership with Adva Biotechnology marking the launch of the groundbreaking ADVA X3® platform in North America.
-
Theragent And Pluristyx Enter Partnership To Streamline And Advance iPSC-derived Therapy Development
5/7/2024
Theragent Inc., a comprehensive CDMO focused on advancing next-generation cell- and tissue-based therapies, has announced a partnership with Pluristyx, Inc., an early stage, privately held biotechnology company specializing in induced Pluripotent Stem Cell (iPSC) products.
-
CytomX Therapeutics Announces Clinical Collaboration With Merck To Evaluate CX-801 In Combination With KEYTRUDA® (pembrolizumab)
5/7/2024
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it has entered into a clinical trial collaboration and supply agreement with Merck (known as MSD outside of the US and Canada) for CytomX’s first-in-human Phase 1 clinical trial assessing the clinical activity of CX-801, a dually-masked interferon-alpha2b cytokine in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab).
-
Selvita Completes Acquisition Of PozLab And Significantly Expands Its Drug Development Capabilities
5/7/2024
Selvita S.A. [WSE: SLV] announced today completion of a strategic transaction in which it has acquired 100% of shares in PozLab. The closing of the transaction comes shortly after the announcement of the transaction on March 27, 2024.
-
Sharp Services Announces Expansion In Pennsylvania To Facilitate Growth In Sterile Injectable Market
5/6/2024
Sharp, a global leader in contract packaging, clinical supply services and small-scale sterile manufacturing, has today announced plans for the expansion of its Macungie, PA site in North America to increase its production capacity for sterile injectables secondary packaging.